Reports on the Food and Drug Administration's (FDA) approval of Proscar, the first drug to treat benign prostatic hyperplasia. Multicenter trial; Side effects; Advice for pregnant women; Generic name finasteride.StroudSallyDyerJanetAmerican Journal of Nursing...
参考来源:Sumitomo Pharma announces positive topline results from phase 3 clinical studies evaluating vibegron in men with overactive bladder symptoms receiving pharmacological therapy for benign prostatic hyperplasia. News release. Sumitomo Pharma. September 11, 2023. 注:以上资讯来源于网络,由香港济民药业整...
Quality of life (QOL) is an important issue when assessing medical treatment of benign prostatic hyperplasia (BPH). There are many QOL questionnaires available, and disease-specific questionnaires are being developed. Currently, most patients undergoing treatment for BPH receive alpha-blockers or finast...
Iconography : Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasiaJohn W KusekAllison AhrensPamela K BurrowsHarry S ClarkeHarris E FosterKaren HansonStephen C JacobsAaron KirkemoKelly O’BerryValory N Pavlik
Benign prostatic hyperplasia and erectile dysfunction are the two major diseases that troubled middle-aged and old men, the concurrency rate of the two diseases is increasing as age increases. Epidemiological studies have shown a significant correlation between the two diseases, therefore, it is of ...
Naftopidil, a phenylpiperazine derivative, is a novel α1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH). Naftopidil competitively inhibited specific [<SUP>3</SUP>H] prazosin binding in prostatic membranes of humans, ...
Provides information pertaining to Proscar, a prescribed drug for the treatment of urinary symptoms associated with an enlarged prostate. Efficacy of the drug to spare some men the prospect of surgery for benign prostatic hyperplasi...
声明: 本网站大部分资源来源于用户创建编辑，上传，机构合作，自有兼职答题团队，如有侵犯了你的权益，请发送邮箱到feedback@deepthink.net.cn 本网站将在三个工作日内移除相关内容,刷刷题对内容所造成的任何后果不承担法律上的任何义务或责任
A predisposition to developing urinary retention such as in benign prostatic hyperplasia Use of monoamine oxidase inhibitors in last 14 days[22] Pregnancy and lactation Its use in pregnant and lactating women is advised against, although the available evidence suggests it is unlikely to cause negative...
A single drug can be used to manage both hypertension and prostatic obstructive symptoms related to benign prostatic hyperplasia (BPH), common problems in older men. Results of a clinical trial showing the efficacy of this monotherapy approach were presented at the 8th Scientific Meeting of the Ame...